Program expands access to CF drug under study

July 16, 2007

s of Aug. 1, patients with cystic fibrosis and Pseudomonas aeruginosa infection who have limited treatment options and are at risk for becoming worse off can access Gilead Sciences' investigational drug aztreonam lysine for inhalation.

As of Aug. 1, patients with cystic fibrosis and Pseudomonas aeruginosa infection who have limited treatment options and are at risk for becoming worse off can access Gilead Sciences' investigational drug aztreonam lysine for inhalation. The Foster City, Calif., company said it is expanding access to the drug to patients who meet its requirements. For more information about the program, call 1-(800) 490-2697 or log on to